Oxford BioMedica inks deal to make AstraZeneca’s potential COVID-19 vaccine

Britain’s Oxford BioMedica has agreed with AstraZeneca to manufacture the drugmaker’s experimental COVID-19 vaccine, the cell therapy company said on Thursday.
Oxford BioMedica will provide the drugmaker withmultiple batches of the vaccine, called AZD1222, under a one-year clinical and commercial supply agreement, the company said, adding that the majority of it is expected be produced throughout 2020.
https://www.reuters.com/article/us-oxford-biomedica-astrazeneca-supply-a/oxford-biomedica-inks-deal-to-make-astrazenecas-potential-covid-19-vaccine-idUSKBN2341VH